Table 1 Clinical evidence on apo-AI HDL infusion
From: Emerging therapeutic strategies to enhance HDL function
Study | Patients | Administration | Result |
|---|---|---|---|
Nicholls et al., [36] | 47 post-acute coronary events (randomized) | Intravenous Apo-AI Milano | 4.6% decrease of lamina elastic interna (measured by ultrasound) |
Nissen et al., [37] | 123 post-acute coronary events (randomized) | Intravenous Apo-AI Milano | 4.2% decrease of atheromatous plaque volume (measured by ultrasound) |
Tardif et al., [40] | 183 patients on coronariography (randomized) | Intravenous reconstituted wild-type HDL | 3.4% decrease of plaque volume (measured by ultrasound) at follow-up(not difference at baseline) |
Shaw et al., [41] | 20 patients with claudication who underwent femoral endarterectomy (randomized) | Intravenous reconstituted wild-type HDL | Decreased expression of vascular cell adhesion molecule-1 and decreased lipid content |